TY  - GEN
AU  - Stopeck,Alison T
AU  - Unger,Joseph M
AU  - Rimsza,Lisa M
AU  - LeBlanc,Michael
AU  - Farnsworth,Brent
AU  - Iannone,Maria
AU  - Glenn,Martha J
AU  - Fisher,Richard I
AU  - Miller,Thomas P
TI  - A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515
SN  - 1528-0020
PY  - 2012///1025
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bevacizumab
KW  - Cyclophosphamide
KW  - Dose-Response Relationship, Drug
KW  - Doxorubicin
KW  - Female
KW  - Humans
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - diagnosis
KW  - Male
KW  - Middle Aged
KW  - Neoadjuvant Therapy
KW  - Prednisone
KW  - Rituximab
KW  - Standard of Care
KW  - Survival Analysis
KW  - Treatment Outcome
KW  - Vincristine
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1182/blood-2012-04-423079
ER  -